RU2004128349A - DRUG TABLET DRUG CONTAINING HUMAN INTERFERON AND / OR INTERFERON INDUCTOR - Google Patents

DRUG TABLET DRUG CONTAINING HUMAN INTERFERON AND / OR INTERFERON INDUCTOR Download PDF

Info

Publication number
RU2004128349A
RU2004128349A RU2004128349/15A RU2004128349A RU2004128349A RU 2004128349 A RU2004128349 A RU 2004128349A RU 2004128349/15 A RU2004128349/15 A RU 2004128349/15A RU 2004128349 A RU2004128349 A RU 2004128349A RU 2004128349 A RU2004128349 A RU 2004128349A
Authority
RU
Russia
Prior art keywords
drug
interferon
tablet
inductor
amount
Prior art date
Application number
RU2004128349/15A
Other languages
Russian (ru)
Other versions
RU2277932C2 (en
Inventor
н Седа Суреновна Григор (RU)
Седа Суреновна Григорян
Феликс Иванович Ершов (RU)
Феликс Иванович Ершов
н Роберт Альбертович Арутюн (RU)
Роберт Альбертович Арутюнян
Original Assignee
н Седа Суреновна Григор (RU)
Седа Суреновна Григорян
Феликс Иванович Ершов (RU)
Феликс Иванович Ершов
н Роберт Альбертович Арутюн (RU)
Роберт Альбертович Арутюнян
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by н Седа Суреновна Григор (RU), Седа Суреновна Григорян, Феликс Иванович Ершов (RU), Феликс Иванович Ершов, н Роберт Альбертович Арутюн (RU), Роберт Альбертович Арутюнян filed Critical н Седа Суреновна Григор (RU)
Priority to RU2004128349/15A priority Critical patent/RU2277932C2/en
Publication of RU2004128349A publication Critical patent/RU2004128349A/en
Application granted granted Critical
Publication of RU2277932C2 publication Critical patent/RU2277932C2/en

Links

Claims (4)

1. Лекарственный препарат противовирусного действия, отличающийся тем, что выполнен в форме таблетки для рассасывания и содержит природный человеческий итерферон (ИФН) или один из рекомбинантных человеческих генно-инженерных ИФНов -α, -β, -γ в низкой дозе 1000МЕ, 2000 ME, 5000ME, 10000МЕ, 20000МЕ или в высокой дозе до 3·106-107ME.1. The antiviral drug, characterized in that it is made in the form of a tablet for resorption and contains natural human interferon (IFN) or one of the recombinant human genetically engineered IFNov -α, -β, -γ in a low dose of 1000ME, 2000 ME, 5000ME, 10000ME, 20000ME or in high dose up to 3 · 10 6 -10 7 ME. 2. Лекарственный препарат по п.1, отличающийся тем, что в качестве действующего вещества содержит смесь равных количеств рекомбинантных человеческих генно-инженерных -α, -β и -γ ИФНов с суммарной активностью, соответствующей низким или высоким дозам препарата.2. The drug according to claim 1, characterized in that the active substance contains a mixture of equal amounts of recombinant human genetic engineering -α, -β and -γ IFNs with a total activity corresponding to low or high doses of the drug. 3. Лекарственный препарат противовирусного действия, отличающийся тем, что выполнен в форме таблетки для рассасывания и содержит индуктор ИФН (ИИФН) из группы ридостин, ларифан, полудан, циклоферон, амиксин, неовир, кагоцел, дибазол, папаверин, кофеин, курантил в количестве от 100 мкг до 25 мг в зависимости от индуктора.3. An antiviral drug, characterized in that it is in the form of a resorption tablet and contains an IFN inducer (IIIF) from the group of ridostin, larifan, poludan, cycloferon, amixin, neovir, kagocel, dibazole, papaverine, caffeine, chimes in an amount from 100 mcg to 25 mg depending on the inductor. 4. Лекарственный препарат по п.3, отличающийся тем, что включает ИИФН в количестве 1/5-1/20 его разовой терапевтической дозы один из рекомбинантных человеческих генно-инженерных - α,-β или -γ ИФНов в количестве 500-1000 ME при их соотношении 2:1-3:1.4. The drug according to claim 3, characterized in that it comprises IIPH in the amount of 1 / 5-1 / 20 of its single therapeutic dose, one of the recombinant human genetic engineering - α, -β or -γ IFNs in the amount of 500-1000 ME with a ratio of 2: 1-3: 1.
RU2004128349/15A 2004-09-24 2004-09-24 Sucking pill containing human interferon and/or interferon inductor possessing antiviral activity RU2277932C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2004128349/15A RU2277932C2 (en) 2004-09-24 2004-09-24 Sucking pill containing human interferon and/or interferon inductor possessing antiviral activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2004128349/15A RU2277932C2 (en) 2004-09-24 2004-09-24 Sucking pill containing human interferon and/or interferon inductor possessing antiviral activity

Publications (2)

Publication Number Publication Date
RU2004128349A true RU2004128349A (en) 2006-03-10
RU2277932C2 RU2277932C2 (en) 2006-06-20

Family

ID=36115670

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2004128349/15A RU2277932C2 (en) 2004-09-24 2004-09-24 Sucking pill containing human interferon and/or interferon inductor possessing antiviral activity

Country Status (1)

Country Link
RU (1) RU2277932C2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2690677C1 (en) 2018-06-27 2019-06-05 Георгий Георгиевич Чумбуридзе Stabilized composition possessing antiviral, anticancer, immunomodulatory, actoprotective, antimutagenic and antioxidant activity

Also Published As

Publication number Publication date
RU2277932C2 (en) 2006-06-20

Similar Documents

Publication Publication Date Title
WO2001060381B1 (en) Nucleoside analogs with carboxamidine-modified bicyclic base
RU2011133741A (en) MODIFIED 2'- AND 3'-NUCLEOSIDES AND THEIR APPLICATION FOR THE PRODUCTION OF A MEDICINE FOR THE TREATMENT OF FLAVIVIRIDAE INFECTIONS
RU2007119725A (en) MEDICINAL FORMS
JP2002515453A5 (en)
EA200200812A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING LOW DOSE OF ENTEKAVIR, AND ITS APPLICATION
RU2009141187A (en) Sulfur-containing compounds as inhibitors of the NS3 seroprotease of the hepatitis C virus
ATE356612T1 (en) ORAL PHARMACEUTICAL DOSAGE FORMS OF LIQUID MEDICATIONS WITH IMPROVED BIOAVAILABILITY
JPS6425A (en) Medicinal composition for treating hiv infection containing dsrna and reverse transcriptase inhibitor
HK1084862A1 (en) Use of omega interferon in the manufacturing of a medicament for treating viral disease in a warm-blooded animal subject
AR036728A1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF INFECTION CAUSED BY THE VIRUS OF HEPATITIS WITH A MULTIPHASTIC INTERFER ADMINISTRATION PROFILE
RU2012136824A (en) METHODS FOR TREATING HEPATITIS C VIRAL INFECTION
MXPA03001039A (en) Improved anti-viral and anti-tumor chemotherapy by administration of erythropoeitin.
HK1086737A1 (en) Kit for pharmaceutical use
RU2004128349A (en) DRUG TABLET DRUG CONTAINING HUMAN INTERFERON AND / OR INTERFERON INDUCTOR
EA200200801A1 (en) Use of follicle-stimulating hormone (FSH) for the treatment of infertility
CN1535724B (en) New application of recombinant human interferon for preventing serious acute respiratory tract syndrome
CN101966176B (en) Application of michelia lactone and derivatives thereof in treatment of hepatitis C
DE69706657T2 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING NATURAL HUMAN ALPHA INTERFERON
ATE83381T1 (en) USE OF RECOMBINATED HUMAN ALPHA INTERFERON IN THE MANUFACTURE OF A MEDICATION FOR THE TREATMENT OF THE AIDS VIRUS.
Roehr Can science meet the challenges of the HCV pandemic: new treatment options for chronic hepatitis C
RU2217161C2 (en) Method for treatment of viral hepatitis
RU94045140A (en) Pharmaceutical composition for prophylaxis and treatment of viral diseases, method of its preparing and use of bradykinin antagonist or its physiologically tolerant salt as agent for prophylaxis and treatment of viral diseases
RU2000105336A (en) DRUG CONTAINING AT LEAST ONE TWO-CHAIN RNA IN A LESS MEASURE ASSOCIATION WITH ONE ANTI-VIRUS
Baker FDA approves new combination treatment for hepatitis C. Food and Drug Administration
JP2005527585A5 (en)

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20140925